📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. (2019)

First Author: O'Sullivan JM
Attributed to:  Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood.2019001861

PubMed Identifier: 31578205

Publication URI: http://europepmc.org/abstract/MED/31578205

Type: Journal Article/Review

Volume: 134

Parent Publication: Blood

Issue: 23

ISSN: 0006-4971